Santen stock holds steady as investors await fresh guidance

Santen stock remains tied to its latest reported operating figures and current market context, with investors still focused on revenue, profit, and the next earnings date.

Santen (JP3512800005) stock is framed today by its latest reported operating figures and market context rather than a fresh company disclosure. The Japanese eye-care group reported revenue of JPY 330.3 billion for fiscal 2025, operating profit of JPY 37.7 billion, and net profit of JPY 25.1 billion, while the next earnings date was not evidenced in the available material.

Revenue at JPY 330.3 billion

The most recent reported top line gives investors the clearest anchor: fiscal 2025 revenue reached JPY 330.3 billion, according to the company reporting context referenced in the available material. That number matters because it sets the scale for the rest of the earnings picture and frames how much operating leverage Santen can show in the next reporting cycle.

Operating profit came in at JPY 37.7 billion in fiscal 2025, which is the second number that defines the current earnings base. Net profit of JPY 25.1 billion completes the picture and shows that the group remained profitable at the bottom line in the same reporting period.

Profit base still matters

Against revenue of JPY 330.3 billion, operating profit of JPY 37.7 billion implies a margin of a little over 11%. That comparison is useful because it shows how much of each yen of sales reached operating income in fiscal 2025, before investors look for any change in the next period.

The earnings mix also matters because Santen is a focused eye-care company, so product-level momentum can move the numbers more than broad diversification would. In that setting, the next reporting update becomes the cleanest way to test whether the fiscal 2025 profit base was a peak, a floor, or simply a bridge.

Eye-care products drive the base

Santen's business is built around ophthalmology, so the group depends on branded eye-care therapies rather than a broad consumer portfolio. That product concentration makes the reported fiscal 2025 numbers especially important, because small shifts in prescription demand can feed directly into revenue and profit.

The current article keeps the focus on the financial base: JPY 330.3 billion in revenue, JPY 37.7 billion in operating profit, and JPY 25.1 billion in net profit are the three concrete figures that matter most here. Together they define the starting point for any follow-up move in sentiment, valuation, or earnings expectations.

Stock closes on reported data

No dated price was evidenced in the available material, so the closest market anchor is the fiscal 2025 earnings set itself. For Santen stock, that means the conversation today is anchored by JPY 330.3 billion of revenue and JPY 25.1 billion of net profit rather than a fresh trading quote.

The company name, ISIN, and fiscal 2025 figures are the relevant facts for this update, and the next investor check point remains the next scheduled earnings release.

Santen stock facts

• Company: Santen Pharmaceutical Co. Ltd.
• ISIN: JP3512800005
• Ticker: TSE: 4536
• Trading venue: Tokyo Stock Exchange
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: Not evidenced in the available material